Two antibodies showing high specificity for PD-1 are now progressing to preclinical development as checkpoint inhibitors in oncology.
Antiverse and GlobalBio, Inc. extend collaboration to advance antibody cancer therapeutics
Antiverse and GlobalBio, Inc. extend…
Antiverse and GlobalBio, Inc. extend collaboration to advance antibody cancer therapeutics
Two antibodies showing high specificity for PD-1 are now progressing to preclinical development as checkpoint inhibitors in oncology.